



DR. DITYA BARDIA, MD, MPH

Assistant Professor, Medicine, Harvard Medical School

Attending Physician, Medical Oncology, Massachusetts General Hospital

BIO: Dr. Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston. As the Director of Precision Oncology Program at the MGH

Center for Breast Cancer, Dr. Bardia is interested in integrating precision diagnostics and therapeutics, including clinical application of circulating tumor cells and DNA as “liquid biopsy”, to significantly improve the outcomes of patients afflicted with breast cancer. Dr. Bardia has led the clinical development of antibody drug conjugate (ADC), sacituzumab govitecan, and selective estrogen receptor degrader (SERD), elacestrant, in metastatic breast cancer. Dr. Bardia has received several research awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, and Douglas Family Foundation prize for excellence in oncology research at MGH. Dr. Bardia is the editor of precision medicine clinic section of *The Oncologist*, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and editorial board member of ASCO molecular oncology tumor board.

PRESENTATION TITLE: *Antibody Drug Conjugates for Treatment of Breast Cancer: The Next Generation of Targeted Chemotherapeutics.*